Replies to post #45354 on OncoSec Medical Inc (ONCSQ)

[dangerM]

Hi Jon Doeuk (so I assume),

to my understanding a TLR7/9 agonist would push some similar levers like our IL-12, but of course not as perfectly.

Why I was wondering about the TLR3: it's directed to the maturation of dendritic cells and is meant to have a complimentary role, such as GM-CSF. The IMHO most important component directed to dendritic cells is still the Flt3L, but still, what would an additional TLR3 do?

Do you know when Dr. Brody has made the statement ("Unpublished data show that the NDV is able to cure around 10% of mice, but with Flt3L it's around 70%.")? He made an appearance after AACR/ASCO in which he even stated a cure rate of 90% (cf. link in https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143444104), which makes me wonder which of these two statements is based on more complete/comprehensive data.

> He has also hinted at using oncolytic viruses over low-dose radiotherapy and TLR agonists.

This could become interesting. Replimune is doing a combo of a HSV (herpes simplex virus, meant to foster the immunogenic cell death of cancer cells and expose their (neo-)antigens) together with GM-CSF (meant to help with maturation of dendritic cells). One of the founders is even the inventor of T-Vec. However, I am sceptical whether they will become as successful as a pIL-12 + Flt3L combo, since: a) One word: herpes, even if it's only the thought of AE years after treatment (just look, Amgen hides the T-Vec/Imlygic sales in "other"). For comparison: Viralytics - which has been bought by Merck - is using a parvovirus i.e. common cold virus with their Cavatak, b) Flt3L appears to be of greater importance to the cDC1 type of dendritic cells than GM-CSF (I summarized something here, https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141917233, please also read hschlauch's preceding message .. the two scientific papers should really be read together).

Thanks for commenting!

dM



P.S.: I have absolutely no idea whats happening right now (the share is rising with very little volume, which is quaint and why I looked here).